KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) EPS (Basic) (2018 - 2025)

Vir Biotechnology (VIR) has disclosed EPS (Basic) for 8 consecutive years, with -$0.3 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 60.53% to -$0.3 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.15 through Dec 2025, up 17.54% year-over-year, with the annual reading at -$3.16 for FY2025, 17.49% up from the prior year.
  • EPS (Basic) hit -$0.3 in Q4 2025 for Vir Biotechnology, up from -$1.17 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $4.04 in Q4 2021 to a low of -$1.56 in Q3 2024.
  • Historically, EPS (Basic) has averaged -$0.18 across 5 years, with a median of -$0.78 in 2022.
  • Biggest five-year swings in EPS (Basic): soared 586.75% in 2021 and later tumbled 220.83% in 2022.
  • Year by year, EPS (Basic) stood at $4.04 in 2021, then crashed by 119.06% to -$0.77 in 2022, then dropped by 11.69% to -$0.86 in 2023, then grew by 11.63% to -$0.76 in 2024, then skyrocketed by 60.53% to -$0.3 in 2025.
  • Business Quant data shows EPS (Basic) for VIR at -$0.3 in Q4 2025, -$1.17 in Q3 2025, and -$0.8 in Q2 2025.